Latest News for: clinical study

Edit

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of

Hastings Tribune 08 Aug 2025
– 94% reduction in HSV-2 shedding rate and 98% reduction in high viral load shedding rate, both statistically significant, observed in cohort evaluating 350 mg weekly oral dose compared to placebo over 29-day evaluation period – ... .
Edit

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor ...

Nasdaq Globe Newswire 08 Aug 2025
– 94% reduction in HSV-2 shedding rate and 98% reduction in high viral load shedding rate, both statistically significant, observed in cohort evaluating 350 mg weekly oral dose compared to placebo over 29-day evaluation period – ... .
Edit

Ongoing Joint Clinical Study Could Pave the Way for Testing Efficacy of Quantum’s Investigational MS drug, Lucid-21-302 (Form 6-K) (Quantum Biopharma Ltd)

Public Technologies 08 Aug 2025
Ongoing Joint Clinical Study Could Pave the Way for Testing Efficacy of Quantum's Investigational MS drug, Lucid-21-302 ... A leading study by Drs ... Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum Biopharma.
Edit

Spermosens: Spermosens provides status update following successful clinical study (Spermosens AB)

Public Technologies 08 Aug 2025
Spermosens provides status update following successful clinical study ... The clinical study, conducted at the Reproductive Medicine ... Spermosens provides status update following successful clinical study.
Edit

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes (Form 8-K) (Assembly Biosciences Inc)

Public Technologies 08 Aug 2025
Assembly Bio's ability to maintain financial resources and secure additional funding necessary to continue its research activities, clinical studies, other business operations and continue as a going ...
Edit

Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor

Hastings Tribune 06 Aug 2025
– Data to date in single- and multiple-ascending dose cohorts of healthy participants demonstrate a four-day half-life for ABI-6250, supporting target daily oral dosing profile and dose-dependent elevations in biomarker of target engagement – ... .
Edit

Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ...

Nasdaq Globe Newswire 06 Aug 2025
– Data to date in single- and multiple-ascending dose cohorts of healthy participants demonstrate a four-day half-life for ABI-6250, supporting target daily oral dosing profile and dose-dependent elevations in biomarker of target engagement – ... .
Edit

Ocumetics Begins Patient Recruitment for First-In-Human Clinical Study of Accommodating Intraocular Lens (Ocumetics Technology Corp)

Public Technologies 05 Aug 2025
). The text version of this document is not available ... Disclaimer ... (noodl. 125770251) .
Edit

Treace Announces Peer-Reviewed Publication of Four-Year Results of the ALIGN3D™ Lapiplasty® Multicenter Prospective Clinical Study

Nasdaq Globe Newswire 05 Aug 2025
TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions ...
Edit

Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 ...

Nasdaq Globe Newswire 05 Aug 2025
0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, ...
Edit

Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS) (Form 6-K) (Quantum Biopharma Ltd)

Public Technologies 05 Aug 2025
Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS).
Edit

Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and ...

The Galveston Daily News 04 Aug 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Aug 4, 2025-- ....
Edit

Marea Therapeutics Enrolls First Patient in Phase 2b TYDAL-TIMI 78 Clinical Study Evaluating MAR001 in ...

The Milton Standard Journal 04 Aug 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Aug 4, 2025-- ....
Edit

Aatru Medical Clinical Study Results Published in PubMed Central/Cureus

The Milton Standard Journal 04 Aug 2025
CLEVELAND--(BUSINESS WIRE)--Aug 4, 2025-- ....
Edit

Ainos Receives TFDA Approval to Initiate Clinical Study of VELDONA for Primary Sj�gren's Syndrome

ACCESSWIRE 04 Aug 2025
... study for primary Sj�gren's syndrome (pSS) ... Harnessing nearly 40 years of research, VELDONA� has demonstrated a strong safety profile and immunomodulatory potential in clinical and preclinical studies.

Article Search

tools
×
×
×
×